Nov. 20 at 11:49 PM
$ABCL
5️⃣ What this means for investors • 2026 = first major efficacy readout (635) • 575 likely monetized via partnership • Platform is built and scaling • Risk now is execution, not survival • AbCellera is entering the real biotech phase shift: platform → validated drug creation
If 635 delivers meaningful efficacy: ABCL will not be a
$5–7 stock anymore.
If 635 fails: ABCL still has 18 clinical programs, 103 total programs,
$600M+ cash, and a validated platform.
This is not a binary biotech story.
⸻
TL;DR
Carl Hansen just told the market: “2026 is the year we prove the platform makes real drugs.”
And that is the moment when a platform company becomes a biopharma
